New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
09:24 EDTVVUS, ATHN, SQNM, BAC, EPOC, ILMN, NSM, RHHBYOn The Fly: Pre-market Movers
HIGHER: Epocrates (EPOC), up 22.6% after agreeing to be acquired by athenahealth (ATHN) for $11.75 per share, in cash... VIVUS (VVUS), up 9.6% after reporting strong growth in Qsymia prescriptions shipped to patients in December... Nationstar Mortgage Holdings (NSM), up 18.6% after confirming deal to acquire about $215B in mortgage servicing assets from Bank of America (BAC). Shares of BofA also up 0.7%... LOWER: Illumina (ILMN), down 9% after acquiring Verinata Health for $350M, Roche's (RHHBY) chairman reportedly says his company no longer looking to acquire Illumina... Sequenom's (SQNM), down 6.5% after reporting preliminary 2012 revenue, which William Blair says may be overshadowed by Illumina's acquisition of Verinata.
News For EPOC;ATHN;NSM;BAC;VVUS;ILMN;SQNM;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 20, 2015
11:33 EDTRHHBYFly Review: Analysts correctly predict jump in Biogen shares
The shares of Biogen (BIIB) are rallying after the company reported results for a Phase 1b study of its Alzheimer's drug, BIIB-037. On March 18, as reported on that day by The Fly, RBC Capital predicted that the stock would rise after the results were published. A number of other firms were also upbeat on the stock ahead of the data release. WHAT'S NEW: Earlier this morning Biogen announced that the three milligram, six milligram, and ten milligram dose versions of its Alzheimer's treatment, aducanumab, had reduced the amount of amyloid plaque in the brains of Alzheimer's patients taking the drug by statistically significant amounts compared with those taking placebos. Beta amyloid is a protein that produces plaque in the brain. Scientists suspect that plaques in the brain are a cause of Alzheimer's. The cognitive decline of patients taking BIIB-037 was also significantly less than that of patients who were taking placebos, the company reported. PRE-EVENT CALLS: RBC Capital analyst Michael Yee predicted earlier this week in a note to investors that Biogen would report strong data for BIIB-037 and the stock should "work higher" after the data is unveiled. Alzheimer's patients taking the high dose of Biogen's BIIB-037 drug should exhibit a stabilization of cognition levels, Yee stated. Conversely, the cognition levels of patients taking the placebo should drop slightly, the analyst predicted. On March 13, in a note summarized by The Fly on that day, JPMorgan recommended buying Biogen shares ahead of the data release. Investors still incorporated a low probability of success for the drug, and the stock could rise further, the firm wrote. On March 19, in a note also published by The Fly, Credit Suisse wrote that Biogen's multiple could rise if the data on BIIB-037 was positive. It raised its price target on the name to $500 from $400. ANALYST REACTION: This morning, Barclays raised Biogen's price target to $500 from $435 following the company's report of "impressive" full results from the Alzheimer's study. Piper Jaffray analyst Joshua Schimmer also raised his price target for Biogen shares to $500 this morning, calling today’s BIIB-037 results "robust and impressive." Schimmer believes the trial showed a "consistent and dramatic" dose effect on both radiographic and clinical disease features and thinks the side effects "pale in comparison" to the drug’s efficacy. OTHERS TO WATCH: Eli Lilly (LLY) and Roche (RHHBY) are also currently developing similar Alzheimer's treatments. PRICE ACTION: In late morning trading, Biogen rose 7% to $464. The stock is up about 9% since Wednesday. Eli Lilly shares are up 1.6% to $75.40 this morning, while Roche rose 2.2% to $35. Reference Link
10:36 EDTBACBank of America changes bylaws to allow some investors to nominate directors
Subscribe for More Information
09:01 EDTRHHBYEli Lilly up 2% to $75.75 in pre-market trading
Subscribe for More Information
05:57 EDTBACBank of America faces pressure to defend structure, Financial Times reports
Bank of America will have to defend its current structure at its annual meeting in May after the SEC allowed a small shareholder the right to challenge the board on a break-up, reports the Financial Times. Bank of America's board could be under pressure to appoint a committee to examine a plan for divesting all non-core banking businesses if a proposal from Barlett Naylor of Public Citizen is adopted. Reference Link
March 19, 2015
17:39 EDTSQNMSequenom launches the HerediT test in collaboration with Recombine
Sequenom's wholly owned subsidiary, Sequenom Laboratories, and Recombine Inc., a clinical genetic testing company dedicated to helping patients and providers make informed healthcare decisions, launched the HerediT UNIVERSAL carrier screening test as a service to ordering physicians. The HerediT UNIVERSAL test screens for more than 250 genetic diseases by analyzing over 2,000 genetic mutations.
16:14 EDTRHHBYProthena report positive results from Phase 1 study of PRX002
Subscribe for More Information
11:53 EDTBACU.S. banks face headwinds in unloading oil loans, WSJ says
Subscribe for More Information
07:59 EDTSQNMSequenom management to meet with William Blair
Subscribe for More Information
07:02 EDTRHHBYSigma-Aldrich signs exclusive distribution agreement with Roche
Subscribe for More Information
06:30 EDTBACSEC says BofA must put investment bank spinoff to shareholder vote, Reuters says
The SEC has told Bank of America that it must allow shareholders to vote on whether the company will attempt to spin off its investment bank unit, reports Reuters, citing a decision by the Securities and Exchange Commission. A bank spokesperson said the company "will respond to the proposal in our proxy statement." Reference Link
06:15 EDTATHNathenahealth coverage transferred with an Outperform at RW Baird
Subscribe for More Information
March 18, 2015
12:48 EDTRHHBYFly Watch: Biogen predicted to report strong Alzheimer's data this Friday
Subscribe for More Information
08:33 EDTILMNTrovagene appoints Matthew Posard as Chief Commercial Officer
Subscribe for More Information
07:46 EDTRHHBYLilly Roche would have upbeat read through from strong BIIB data, says Bernstein
Bernstein notes that the data for Biogen's (BIIB) Alzheimer's treatment, due to be released on Friday, is widely expected to be positive. The firm thinks that positive data would boost the outlook for similar Alzheimer's drugs being developed by Eli Lilly (LLY) and Roche (RHHBY), since consensus estimates for those drugs are low. The firm keeps Outperform ratings on Eli Lilly and Roche.
07:10 EDTBACPlatts to hold a forum
11th Annual Steel Markets North America is being held in Chicago on March 17-18.
March 17, 2015
08:34 EDTBACBank of America reinstated with an Outperform at Raymond James
Subscribe for More Information
08:13 EDTRHHBYCelldex announces clinical trial collaboration with Roche
Celldex Therapeutics (CLDX) announced that it has entered into a clinical trial collaboration with Roche (RHHBY) to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A, Roche's investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma. Varlilumab and MPDL3280A are part of a new class of investigational medicines known as cancer immunotherapies that are designed to harness the body's own immune system to fight cancer through separate yet complementary mechanisms of action that may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells. Preclinical data suggest the combination of these two mechanisms are synergistic and may enhance anti-tumor immune response compared to either agent alone. In Celldex's Phase 1 study of varlilumab in multiple solid tumors, promising signs of clinical activity in patients with refractory renal cell carcinoma were observed, including a durable partial response that has continued to decrease in tumor volume over time and prolonged stable disease. Under the terms of this agreement, Roche will provide study drug and Celldex will be responsible for conducting and funding the study, which is expected to begin in 2015.
07:05 EDTSQNMSequenom elects Kenneth Buechler as Chairman of the Board
Sequenom elected Kenneth Buechler as Chairman of the Board, effective April 1, 2015. Buechler succeeds Harry Hixson who will retire from the position effective March 31 after 11 years of service. Incoming chairman, Dr. Buechler, has served on the board of directors since December 2009. Prior to joining Sequenom's board, he served as President and Chief Scientific Officer of Biosite Incorporated, which he co-founded.
March 16, 2015
10:22 EDTBACBank of America February default rate 2.98% vs. 2.93% last month
Reports February delinquency rate 1.86% vs. 1.83% last month.
05:40 EDTILMN, SQNMIllumina files patent infringement suit in UK regarding NIPT patents
Illumina (ILMN) announced that it and its wholly-owned subsidiary, Verinata Health have filed a patent infringement suit against Premaitha Health in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief. The patents asserted are European Patent 0 994 963 B2 and European Patent 1 981 995 B1, which are exclusively licensed to Illumina from Sequenom (SQNM), and The Board of Trustees of Leland Stanford Junior University, respectively. Stanford is joined in the suit as a necessary party because it is the registered owner of the European Patent 1 981 995 B1. The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing. The suit accuses Premaitha’s IONA Test of infringement, including its use of next-generation sequencing to analyze cell-free fetal DNA from a sample of maternal blood.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use